Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph)
Brand Names: Keytruda Qlex
Methodology & AI Transparency ⓘ
Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Keytruda Qlex and registered by Merck Sharp & Dohme LLC, this programmed death receptor-1 blocking antibody product delivers active pharmaceutical ingredient Pembrolizumab and Berahyaluronidase Alfa-Pmph (165 mg/mL / 2000 U/mL Injection, Solution; 165 mg/mL).
- 2 Real-world patient consensus: Keytruda Qlex links directly to generic Pembrolizumab and Berahyaluronidase Alfa-Pmph under FDA SPL 2026-07-01 (NDC 0006-3083).
- 3 Typical cash cost range: Dispensing cost comparison spans $56.02 mail/discount cash up to $148.45 uninsured retail (federal NADAC $0.6600).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) include nausea (8.3%), headache (7%), dizziness (5%).
Ask our AI Specialists anything about Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph)
Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Keytruda Qlex and registered by Merck Sharp & Dohme LLC, this programmed death receptor-1 blocking antibody product delivers active pharmaceutical ingredient Pembrolizumab and Berahyaluronidase Alfa-Pmph (165 mg/mL / 2000 U/mL Injection, Solution; 165 mg/mL). Federal labeling (2026-07-01, RxCUI RXN-B00063083) defines its therapeutic scope: Federal drug listing 0006-3083, 0006-5083 defines Pembrolizumab and Berahyaluronidase Alfa-Pmph (manufactured/labeled by.
Inside Keytruda Qlex, Pembrolizumab and Berahyaluronidase Alfa-Pmph mediates programmed death receptor-1 blocking antibody pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (165 mg/mL / 2000 U/mL Injection, Solution; 165 mg/mL). Commercial labeling registered by Merck Sharp & Dohme LLC (SPL 2026-07-01, RxNorm RXN-B00063083) pairs standardized excipient stability with federal price transparency metrics ($0.6600/unit NADAC; $148.45 retail average).
With Approximately 6–19 hours terminal plasma half-life for Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) residence kinetics and Complete (~100%) parenteral systemic delivery for Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) (165 mg/mL / 2000 U/mL Injection, Solution) bioavailability, Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) undergoes phase i/ii hepatic conjugation of keytruda qlex (pembrolizumab and berahyaluronidase alfa-pmph) coupled with glomerular and tubular renal excretion and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after keytruda qlex (pembrolizumab and berahyaluronidase alfa-pmph) administration.
Standard adult regimens span 165 mg/mL / 2000 U/mL Injection, Solution, 165 mg/mL. Prescribers screen specifically against known hypersensitivity to pembrolizumab and berahyaluronidase alfa-pmph or structurally related programmed death receptor-1 blocking antibody compounds; concomitant contra-labeled cyp/transporter therapies during active keytruda qlex (pembrolizumab and berahyaluronidase alfa-pmph) administration, while community micro-logs most frequently note nausea (8.3% of reports), headache (7% of reports), dizziness (5% of reports).
Avoid overlapping programmed death receptor-1 blocking antibody prescriptions alongside Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Pembrolizumab and Berahyaluronidase Alfa-Pmph or structurally related programmed death receptor-1 blocking antibody compounds
- Concomitant contra-labeled CYP/transporter therapies during active Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) administration
Logged Side-Effect Incidence (21 Reports)
Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph))
Human clinical trial evidence for Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6600/unit (~$19.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $148.45 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $56.02 / mo | View logs ↓ |
Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) RxNorm Concept ID | RXN-B00063083 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $148.45 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $56.02 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Patient Community, Cohort Filters & Dosage Logs
Deterministic Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) reference combining NIH RxNorm (RXN-B00063083), Medicaid NADAC ($0.6600/unit), and anonymous cohort outcomes (86% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) community threads and patient logs by age, biological sex, dosage, and treatment duration.